High Dropout Rates for New Weight-Loss Drugs Due to Costs and Side Effects

A new study by the Blue Cross Blue Shield Association reveals that over 30% of people taking GLP-1 weight-loss drugs like Ozempic and Wegovy stop their treatment within four weeks, often due to early side effects and high costs. This premature discontinuation is more common among younger adults and those in underserved areas. Experts emphasize the importance of completing at least 12 weeks of treatment to achieve significant weight loss and maintain health benefits, as stopping early often leads to regaining most of the lost weight.